$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019428 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$4.160M	$3.603M	$100.0M
YoY Change	69.24%	-37.98%	55148.62%
Cost Of Revenue	$769.0K	$684.0K	$954.0K
YoY Change	-66.46%	-50.29%	148.44%
Gross Profit	$3.391M	$2.919M	$3.885M
YoY Change	1955.15%	-34.15%	-2013.79%
Gross Profit Margin	81.51%	81.02%	3.89%
Selling, General & Admin	$4.510M	$5.169M	$5.882M
YoY Change	-36.47%	-30.82%	-42.1%
% of Gross Profit	133.0%	177.08%	151.4%
Research & Development	$270.0K	$594.0K	$1.383M
YoY Change	-32.84%	10.0%	-18.17%
% of Gross Profit	7.96%	20.35%	35.6%
Depreciation & Amortization	$7.000K	$12.00K	$22.00K
YoY Change	-95.95%	-95.1%	-91.2%
% of Gross Profit	0.21%	0.41%	0.57%
Operating Expenses	$4.780M	$5.763M	$7.265M
YoY Change	-36.28%	-28.07%	-38.69%
Operating Profit	-$1.389M	-$2.844M	-$3.380M
YoY Change	-81.07%	-20.54%	-71.95%
Interest Expense	$3.306M	$564.0K	$1.853M
YoY Change	-3693.48%	-0.18%	-58.72%
% of Operating Profit
Other Income/Expense, Net	$2.748M	-$1.965M	-$587.0K
YoY Change	-325.43%	-260.02%	-23.27%
Pretax Income	$1.359M	-$4.809M	-$2.114M
YoY Change	-115.89%	104.55%	-74.62%
Income Tax	$8.000K		$0.00
% Of Pretax Income	0.59%
Net Earnings	$1.351M	-$4.809M	-$5.098M
YoY Change	-115.79%	104.29%	-55.59%
Net Earnings / Revenue	32.48%	-133.47%	-5.1%
Basic Earnings Per Share	$0.02	-$0.16
Diluted Earnings Per Share	$0.00	-$0.16	-$0.43
COMMON SHARES
Basic Shares Outstanding	62.06M shares	45.94M shares	10.73M shares
Diluted Shares Outstanding	1.614B shares	31.19M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$1.537M	$1.311M	$1.775M
YoY Change	-51.11%	-56.2%	-48.18%
Inventory	$1.060M	$1.306M	$1.697M
Prepaid Expenses
Receivables	$4.617M	$4.306M	$5.738M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.214M	$6.923M	$9.210M
YoY Change	-39.96%	-58.08%	-27.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.187M	$1.200M	$1.203M
YoY Change	-28.84%	-67.55%	-69.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$35.00K	$35.00K
YoY Change	-81.54%	-98.18%	-99.15%
Total Long-Term Assets	$1.337M	$1.294M	$1.344M
YoY Change	-35.03%	-86.41%	-89.22%
TOTAL ASSETS
Total Short-Term Assets	$7.214M	$6.923M	$9.210M
Total Long-Term Assets	$1.337M	$1.294M	$1.344M
Total Assets	$8.551M	$8.217M	$10.55M
YoY Change	-39.24%	-68.44%	-58.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.03M	$16.29M	$17.02M
YoY Change	-6.52%	-13.32%	13.59%
Accrued Expenses	$4.752M	$4.575M	$4.227M
YoY Change	12.71%	32.46%	2.5%
Deferred Revenue	$3.600M	$3.200M	$3.200M
YoY Change
Short-Term Debt	$397.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due	$42.89M	$42.35M	$43.27M
YoY Change	-0.27%	-16.36%	-34.13%
Total Short-Term Liabilities	$73.18M	$74.24M	$72.46M
YoY Change	4.97%	-6.98%	-22.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.000K	$4.000K	$8.000K
YoY Change	-95.45%	-99.85%	-99.74%
Total Long-Term Liabilities	$1.000K	$4.000K	$8.000K
YoY Change	-95.45%	-99.85%	-99.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$73.18M	$74.24M	$72.46M
Total Long-Term Liabilities	$1.000K	$4.000K	$8.000K
Total Liabilities	$73.18M	$74.24M	$72.47M
YoY Change	4.93%	-9.94%	-25.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$892.3M	-$893.6M	-$888.7M
YoY Change	-6.03%	-5.04%	-5.33%
Common Stock	$8.000K	$5.000K	$2.000K
YoY Change		-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$69.32M	-$70.67M	-$66.51M
YoY Change
Total Liabilities & Shareholders Equity	$8.551M	$8.217M	$10.55M
YoY Change	-39.24%	-68.44%	-58.06%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$1.351M	-$4.809M	-$5.098M
YoY Change	-115.79%	104.29%	-55.59%
Depreciation, Depletion And Amortization	$7.000K	$12.00K	$22.00K
YoY Change	-95.95%	-95.1%	-91.2%
Cash From Operating Activities	-$1.141M	$123.0K	-$170.0K
YoY Change	-23.63%	-102.49%	-97.4%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$14.00K	$0.00
YoY Change	-100.0%	366.67%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$14.00K	$0.00
YoY Change	-100.0%	366.67%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.144M		340.0K
YoY Change	91.62%		-77.33%
NET CHANGE
Cash From Operating Activities	-1.141M	$123.0K	-170.0K
Cash From Investing Activities	0.000	-$14.00K	0.000
Cash From Financing Activities	1.144M		340.0K
Net Change In Cash	3.000K	$109.0K	170.0K
YoY Change	-100.33%	-103.36%	-103.36%
FREE CASH FLOW
Cash From Operating Activities	-$1.141M	$123.0K	-$170.0K
Capital Expenditures	$0.00	$14.00K	$0.00
Free Cash Flow	-$1.141M	$109.0K	-$170.0K
YoY Change	-23.68%	-102.21%	-97.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends		usd
CY2023Q1	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes		usd
CY2023Q1	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants		usd
CY2024Q1	EVFM	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses		usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4575000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3261000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2609000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4310000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3391000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3316000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	74239000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72463000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	74243000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	72471000	usd
CY2024Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4640000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4593000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48710395	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48710395	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20007799	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20007799	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	823409000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	823036000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-525000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-849000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-893555000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888699000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8217000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10554000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3603000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5809000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	684000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1376000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	594000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	540000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2345000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3854000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2824000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3618000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	6447000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	9388000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2844000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3579000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	usd
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	616000	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	318000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3275000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-84000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1120000	usd
CY2024Q1	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	802000	usd
CY2023Q1	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1612000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1965000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1228000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4809000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2351000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2024Q1	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends	-47000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4856000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2354000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31194393	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31194393	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1271524	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1271524	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	324000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	15460000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4485000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	13106000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	15000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	89000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	237000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	47000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2023Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	67000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1629000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	15460000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-56401000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-56401000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3275000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-84000	usd
CY2024Q1	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	802000	usd
CY2023Q1	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1612000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1120000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	237000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	417000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	12000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	245000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	564000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	565000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	47000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	504000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-5000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1432000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6278000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-391000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	99000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-573000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1518000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-726000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3813000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	438000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-352000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	652000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-800000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-46000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-591000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	123000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4940000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	61000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1640000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1701000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	109000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3242000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1534000	usd
CY2024Q1	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	-89000	usd
CY2023Q1	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	-180000	usd
CY2024Q1	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	78000	usd
CY2023Q1	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	140000	usd
CY2024Q1	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends	47000	usd
CY2024Q1	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes	-35000	usd
CY2024Q1	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants	15000	usd
CY2023Q1	EVFM	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	-125000	usd
CY2024Q1	EVFM	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	67300000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-893600000	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zCqrr10Ckam8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zVGGG9WZu46c">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in <a href="#nt_003">Note 3 – Revenue</a>, <a href="#nt_004">Note 4 – Debt</a>, <a href="#nt_06">Note 6 - Fair Value of Financial Instruments</a>, <a href="#nt_07">Note 7 - Commitments and Contingencies</a>, and <a href="#nt_009">Note 9 - Stock-based Compensation</a>. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zWu1V2jlnDCe" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z3AgLRBhskZe">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of March 31, 2024, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phexxi is distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute Phexxi on demand as orders are received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2024, and 2023, the Company’s three largest customers combined made up approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEFI0fVscx7l">82</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOzBCE6AZoGc">86</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of its gross product sales, respectively. As of March 31, 2024 and December 31, 2023, the Company’s three largest customers combined made up <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsUsEP07xuy5">89</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIOetNBd5o8a">87</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, respectively, of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	639000	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	689000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	895000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1534000	usd
CY2023Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5513316258	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35466940	shares
CY2024Q1	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	200000	usd
CY2023Q4	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	300000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3200000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3200000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0158
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	92700000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023Q3	EVFM	Cumulative Net Sales CumulativeNetSales	100000000	usd
CY2023Q3	EVFM	Accrued Interest Agreement Percentage AccruedInterestAgreementPercentage	0.10	pure
CY2023Q4	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023Q3	us-gaap	Long Term Debt Contingent Payment Of Principal Or Interest LongTermDebtContingentPaymentOfPrincipalOrInterest	The cash payments will be determined based upon the quarterly global net revenue of Phexxi such that if the global net revenue is less than or equal to $5.0 million, the Company will pay 3% of such global net revenues; if the global net revenue is over $5.0 million and less than or equal to $7.0 million, the Company will continue to pay 3% on net revenue up to $5.0 million and 4% on the net revenue over $5.0 million; and if the global net revenue is over $7.0 million, the Company will pay 3% on the net revenue up to $5.0 million, 4% on the net revenue over $5.0 million up to $7.0 million, and 5% on net revenue over $7.0 million. The cash payments were payable beginning in the fourth quarter of 2023. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $1.0 million upfront payment, will be deducted from the Repurchase Price as Applicable Reductions.
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75300000	usd
CY2023	EVFM	Revalued Amount Extinguishment Of Debt Amount RevaluedAmountExtinguishmentOfDebtAmount	73200000	usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	536000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	497000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	68000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	564000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	565000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	520000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	386000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	780000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	791000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1306000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2024Q1	us-gaap	Inventory Adjustments InventoryAdjustments	200000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1300000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	314000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	777000	usd
CY2024Q1	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	13000	usd
CY2023Q4	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	13000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	295000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	405000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	622000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1889000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2389000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	689000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1186000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1200000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2024Q1	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2023Q4	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1336000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1146000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	741000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	583000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4575000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4310000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
CY2024Q1	EVFM	Number Of Leased Vehicles NumberOfLeasedVehicles	20	integer
CY2019Q4	EVFM	Office Square Footage OfficeSquareFootage	24474	sqft
CY2020Q2	EVFM	Office Square Footage OfficeSquareFootage	8816	sqft
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4200000	usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000	usd
CY2022Q2	EVFM	Lessee Operating Sublease Rentable Area LesseeOperatingSubleaseRentableArea	16637	sqft
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2022Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.035	pure
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	300000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	56000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	456000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	56000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	67000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	59000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	64000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	610000	usd
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	2100000	usd
CY2024Q1	EVFM	Accounts Payable Trade90 Days Past Due Or More Percent AccountsPayableTrade90DaysPastDueOrMorePercent	0.94	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	894194	shares
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	9972074	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.42
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	20807543000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	2300	shares
CY2023Q3	EVFM	Debt Instrument Redemption Premium In Event Of Default DebtInstrumentRedemptionPremiumInEventOfDefault	0.25	pure
CY2023	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	1800000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q1	EVFM	Common Stock Reserved Upon Exercise Of Stock Options Outstanding CommonStockReservedUponExerciseOfStockOptionsOutstanding	3747	shares
CY2024Q1	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10598205	shares
CY2024Q1	EVFM	Common Stock Capital Share Reserved For Future Issuance CommonStockCapitalShareReservedForFutureIssuance	722646377	shares
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	148541458	shares
CY2024Q1	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	33750860	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	915547554	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	417000	usd

Files In Submission

Name	View Source	Status
0001493152-24-019428-index-headers.html	Edgar Link	pending
0001493152-24-019428-index.html	Edgar Link	pending
0001493152-24-019428.txt	Edgar Link	pending
0001493152-24-019428-xbrl.zip	Edgar Link	pending
evfm-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
evfm-20240331_def.xml	Edgar Link	unprocessable
evfm-20240331_lab.xml	Edgar Link	unprocessable
evfm-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
evfm-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2024 Q2 Form 10-Q Financial Statement

#000149315224019428 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2024 Q2 Form 10-Q Financial Statement

#000149315224019428 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm